By effortlessly integrating with any EHR system and listening in on the clinician’s chat with the patient, TORTUS automates clinical documentation for final sign-off.
TORTUS, a healthtech firm using generative AI, announced today that Khosla Ventures is leading a $4.2 million seed investment.
The company’s flagship product, O.S.L.E.R. (Operating System Leverage in Electronic Records), listens to the clinician’s conversation with the patient and seamlessly integrates with any electronic health records (EHR) system to automate the clinical documentation process for final sign-off by clinicians. This includes pre-chart summaries, visit notes, lab requests, coding, and more.
Consequently, physicians are able to devote their entire focus to patients throughout consultations and allocate time for paperwork.
In addition, TORTUS today revealed a first-of-its-kind pilot program with Great Ormond Street Hospital, a famous medical facility, where its technology will be assessed in clinical settings. Data regarding the technology’s effects on clinical workload and patient experience will be gathered and analyzed by researchers.
Furthermore, TORTUS becomes the first company in the UK to comply with the NHS DTAC standard for AI technology.
In addition to Entrepreneur First, former NHS Chair Lord David Prior, and other investors, Khosla Ventures led the Seed round. Chief Scientific Advisor Eric Jang, VP of AI at 1X Technologies, also joined.
In order to give physicians even more time back, the additional funding will be utilized to expedite the development and compliance of the O.S.L.E.R. agent. This will involve expanding its present capabilities to include making prescription orders, adding diagnoses, and coding to the system.
Along with growing into new hospitals and primary care facilities, the company has other primary care sites scheduled to launch in February 2024.
